Antibody-Exatecan Conjugates with a Novel Self-Immolative Moiety Overcome Resistance in Colon and Lung Cancer

The authors designed an antibody-drug conjugates class using a novel self-immolative T moiety for traceless conjugation and release of exatecan, a more potent Topoisomerase I inhibitor with less sensitivity to multidrug resistance.
[Cancer Discovery]

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News